Tags

Type your tag names separated by a space and hit enter

[First results of clinical studies on botulinum toxin A in migraine and headache].
Nervenarzt 2008; 79 Suppl 1:44-6N

Abstract

Today, botulinumtoxin A (BoNT-A) is applied for a broad spectrum of therapeutic uses. Experimental and clinical studies indicate that it also affects certain kinds of pain. One example of its prophylactic use is for chronic daily headache (CDH), defined as 15 days per month with headache. As shown by subgroup analyses in a phase II study, patients treated with BoNT-A and no additional treatment had significantly more pain-free days than those treated with placebo. They also required less frequent administration of headache medicines. Important was also the recognition that repeat treatments with BoNT-A at dosages of up to 260 U were safe and showed no difficult side effects. Phase III clinical studies are already being conducted.

Authors+Show Affiliations

Pharm-Allergan GmbH, Ettlingen. Tiesler_Ulrich@Allergan.com

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

18927967

Citation

Tiesler, U. "[First Results of Clinical Studies On Botulinum Toxin a in Migraine and Headache]." Der Nervenarzt, vol. 79 Suppl 1, 2008, pp. 44-6.
Tiesler U. [First results of clinical studies on botulinum toxin A in migraine and headache]. Nervenarzt. 2008;79 Suppl 1:44-6.
Tiesler, U. (2008). [First results of clinical studies on botulinum toxin A in migraine and headache]. Der Nervenarzt, 79 Suppl 1, pp. 44-6.
Tiesler U. [First Results of Clinical Studies On Botulinum Toxin a in Migraine and Headache]. Nervenarzt. 2008;79 Suppl 1:44-6. PubMed PMID: 18927967.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [First results of clinical studies on botulinum toxin A in migraine and headache]. A1 - Tiesler,U, PY - 2008/10/18/pubmed PY - 2008/11/19/medline PY - 2008/10/18/entrez SP - 44 EP - 6 JF - Der Nervenarzt JO - Nervenarzt VL - 79 Suppl 1 N2 - Today, botulinumtoxin A (BoNT-A) is applied for a broad spectrum of therapeutic uses. Experimental and clinical studies indicate that it also affects certain kinds of pain. One example of its prophylactic use is for chronic daily headache (CDH), defined as 15 days per month with headache. As shown by subgroup analyses in a phase II study, patients treated with BoNT-A and no additional treatment had significantly more pain-free days than those treated with placebo. They also required less frequent administration of headache medicines. Important was also the recognition that repeat treatments with BoNT-A at dosages of up to 260 U were safe and showed no difficult side effects. Phase III clinical studies are already being conducted. SN - 0028-2804 UR - https://www.unboundmedicine.com/medline/citation/18927967/[First_results_of_clinical_studies_on_botulinum_toxin_A_in_migraine_and_headache]_ L2 - http://www.diseaseinfosearch.org/result/4811 DB - PRIME DP - Unbound Medicine ER -